Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Common Equity (2024 - 2025)

Historic Common Equity for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $58.5 million.

  • Prelude Therapeutics' Common Equity fell 6258.16% to $58.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.5 million, marking a year-over-year decrease of 6258.16%. This contributed to the annual value of $131.5 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Common Equity is $58.5 million, which was down 6258.16% from $75.8 million recorded in Q2 2025.
  • Prelude Therapeutics' Common Equity's 5-year high stood at $210.7 million during Q1 2024, with a 5-year trough of $58.5 million in Q3 2025.